A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

PURPOSE: Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy. METHODS: As part of a phase I trial in patients with advanced solid tumors (NCT00809133; 3 + 3 dose-escalation design), we determined the maximum tolerated dose (MTD) of afatini...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Chemother Pharmacol
Main Authors: O’Brien, Mary E. R., Sarker, Debashis, Bhosle, Jaishree, Thillai, Kiruthikah, Yap, Timothy A., Uttenreuther-Fischer, Martina, Pemberton, Karine, Jin, Xidong, Wiebe, Sabrina, de Bono, Johann, Spicer, James
格式: Artigo
語言:Inglês
出版: Springer Berlin Heidelberg 2018
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182763/
https://ncbi.nlm.nih.gov/pubmed/30088048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-018-3661-1
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍